Literature DB >> 29072563

Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma.

Nedal Bukhari1, Eric Winquist1.   

Abstract

Entities:  

Year:  2017        PMID： 29072563      PMCID： PMC5698026          DOI： 10.5489/cuaj.4519

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  10 in total

Review 1.  Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review.

Authors:  Wenge Wang; Jihua Cheng; Carol Mallon; Mohammed Y Al-Marrawi; Sheldon Holder; Monika Joshi; Matthew Kaag; Giampaolo Talamo; Joseph J Drabick
Journal:  Clin Genitourin Cancer       Date:  2015-07-26       Impact factor: 2.872

2.  Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma.

Authors:  Ingrid Alexandre; Bertrand Billemont; Jean Baptiste Meric; Stephane Richard; Olivier Rixe
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

3.  Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

Authors:  Doru T Alexandrescu; Rebecca McClure; Haleh Farzanmehr; Constantin A Dasanu
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

4.  Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy.

Authors:  Daniel M Moreira; Boris Gershman; Christine M Lohse; Stephen A Boorjian; John C Cheville; Bradley C Leibovich; Robert Houston Thompson
Journal:  World J Urol       Date:  2016-02-25       Impact factor: 4.226

5.  Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy.

Authors:  Abhishek Tripathi; Susanna Jacobus; Hope Feldman; Toni K Choueiri; Lauren C Harshman
Journal:  Clin Genitourin Cancer       Date:  2016-12-13       Impact factor: 2.872

6.  Leukemia kidney infiltration can cause secondary polycythemia by activating hypoxia-inducible factor (HIF) pathway.

Authors:  Tomoo Osumi; Midori Awazu; Eriko Fujimura; Fumito Yamazaki; Akinori Hashiguchi; Hiroyuki Shimada
Journal:  Eur J Pediatr       Date:  2013-05-16       Impact factor: 3.183

7.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

8.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

Review 9.  Role of vascular endothelial growth factor in kidney disease.

Authors:  Kent Doi; Eisei Noiri; Toshiro Fujita
Journal:  Curr Vasc Pharmacol       Date:  2010-01       Impact factor: 2.719

10.  Successful treatment of erythropoietin-producing advanced renal cell carcinoma after targeted therapy using sunitinib: Case report and review of the literature.

Authors:  Kosuke Ueda; Shigetaka Suekane; Katsuaki Chikui; Makoto Nakiri; Fukuko Moriya; Tokumasa Hayashi; Jiro Miyajima; Kei Matsuoka
Journal:  Mol Clin Oncol       Date:  2012-08-03
  10 in total
  2 in total

1.  Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis.

Authors:  Shota Kodaira; Jun Ehara; Shigemasa Takamizawa; Shin Ogita; Yasuhiro Norisue; Tatsuya Nakama; Eiji Hiraoka
Journal:  Am J Case Rep       Date:  2021-09-07

2.  Metastatic Type II Papillary Renal Cell Carcinoma With Recurrent Complete Responses to Sunitinib: A Case Report With a Literature Review.

Authors:  Bayan H Al Ashour; Faisal Azam; Fahad Ibnshamsah; Fahad Alrowais; Ayed Al-Garni; Humaid O Al-Shamsi; Nedal Bukhari
Journal:  Cureus       Date:  2022-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.